FDA Loosens Reins on Crisis Lab Tests for Speed
Published Date: 9/23/2025
Notice
Summary
The FDA just released new rules about how they’ll handle certain lab tests during emergencies, like a health crisis. If you make or use these tests, this guidance explains when the FDA might relax some rules to help get tests out faster. This means quicker access to important tests without waiting for all the usual approvals, saving time and possibly money during emergencies.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
FDA may relax rules for IVD makers
The FDA guidance explains the factors it will use to decide whether to issue an enforcement policy that allows manufacturers to offer certain unapproved in vitro diagnostic (IVD) tests or unapproved uses of approved IVD tests during a Section 564 declared emergency. If the FDA issues such an enforcement policy, makers could be allowed to provide tests without completing the usual approvals during that declared emergency.
Faster access to certain tests in emergencies
During a Section 564 declared emergency, the FDA may issue enforcement policies that allow certain unapproved IVD tests or unapproved uses of approved tests to be offered. You could get access to some lab tests sooner in that declared emergency because the guidance explains when the FDA might permit those offerings.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11740 — Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
2026-11589 — Medical Devices; Ear, Nose, and Throat Devices; Classification of the Combined Acoustic and Electrical External Stimulation Device for the Relief of Tinnitus
The FDA has officially placed the combined acoustic and electrical external stimulation device for tinnitus relief into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification is effective June 10, 2026, with the rules applying retroactively from March 6, 2023.
2026-11578 — Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information
The FDA just gave a thumbs-up to adding bemotrizinol as a new active ingredient in sunscreens, letting it be used up to 6% concentration. This means sunscreen makers can now include this ingredient, which is safe and effective, in their products. The change is official as of June 10, 2026, and could lead to better sun protection options without extra costs for consumers.
Previous / Next Documents
Previous: 2025-18401 — Multilayered Wood Flooring From the People's Republic of China: Notice of Court Decision Not in Harmony With the Results of Countervailing Duty Administrative Review; Notice of Amended Final Results
The U.S. Court of International Trade made a final decision about taxes on multilayered wood flooring from China for 2017. Because of this, the Department of Commerce is changing the subsidy rates (extra fees) for some companies like Jiangsu Senmao and Riverside Plywood, but not for Jiangsu Guyu. If you’re involved with these companies or import this flooring, expect updated fees and official changes soon.
Next: 2025-18404 — Evaluation of the Georgia Coastal Management Program; Notice of Public Meeting; Request for Comments
NOAA is checking how well Georgia’s Coastal Management Program is working and wants your thoughts! If you live near Georgia’s coast or care about protecting it, now’s your chance to join a virtual meeting or send in comments. This review could shape future plans and funding to keep Georgia’s coast safe and beautiful.